Literature DB >> 20002539

APC resistance: biological basis and acquired influences.

E Castoldi1, J Rosing.   

Abstract

Proteolytic inactivation of factors Va (FVa) and VIIIa (FVIIIa) by activated protein C (APC) and its cofactors protein S and factor V (FV) is a key process in the physiological down-regulation of blood coagulation. Functional abnormalities of this pathway, which manifest themselves in vitro as a poor anticoagulant response of plasma to added APC (APC resistance), are prevalent in the general population and are associated with an increased risk of venous thrombosis. APC resistance was originally discovered in thrombophilic families and later shown to be associated with the common FV Arg506Gln (FV(Leiden)) mutation, which abolishes one of the APC-cleavage sites in FV. Although FV(Leiden) is the major cause of hereditary APC resistance, it is becoming increasingly clear that several other genetic and acquired conditions contribute to APC resistance and thereby increase the risk of venous thrombosis. This paper reviews the multifactorial etiology of APC resistance and discusses its clinical implications.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20002539     DOI: 10.1111/j.1538-7836.2009.03711.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  19 in total

Review 1.  Extracellular Matrix Reorganization During Wound Healing and Its Impact on Abnormal Scarring.

Authors:  Meilang Xue; Christopher J Jackson
Journal:  Adv Wound Care (New Rochelle)       Date:  2015-03-01       Impact factor: 4.730

Review 2.  Mechanisms of anticoagulant and cytoprotective actions of the protein C pathway.

Authors:  E A M Bouwens; F Stavenuiter; L O Mosnier
Journal:  J Thromb Haemost       Date:  2013-06       Impact factor: 5.824

Review 3.  Protein C anticoagulant and cytoprotective pathways.

Authors:  John H Griffin; Berislav V Zlokovic; Laurent O Mosnier
Journal:  Int J Hematol       Date:  2012-04-05       Impact factor: 2.490

4.  Evaluation of role of FV, FVIII and APLAs in the pathogenesis of APCR in FV Leiden negative DVT patients: a study in India.

Authors:  Amit Sharma; Kanwaljeet Singh; Arijit Biswas; Ravi Ranjan; Kamal Kishor; Ravi Kumar; Hareram Pandey; Vineet Kumar Kamal; Renu Saxena
Journal:  J Thromb Thrombolysis       Date:  2017-02       Impact factor: 2.300

5.  Primary Thrombophilia in México XI: Activated Protein C Resistance Phenotypes are Multifactorial.

Authors:  Ma Fernanda Vallejo-Villalobos; Andrés León-Peña; Mónica León-González; Ana Karen Núñez-Cortés; Juan Carlos Olivares-Gazca; Patricia Valdés-Tapia; Javier Garcés-Eisele; Alejandro Ruiz-Argüelles; Guillermo J Ruiz-Argüelles
Journal:  Indian J Hematol Blood Transfus       Date:  2016-12-19       Impact factor: 0.900

6.  Prothrombotic risk factors and antithrombotic therapy in children with ischemic stroke.

Authors:  Azza A Eltayeb; Gamal A Askar; Naglaa H Abu Faddan; Taghreed M Kamal
Journal:  Ther Adv Neurol Disord       Date:  2015-03       Impact factor: 6.570

7.  Survival advantage of heterozygous factor V Leiden carriers in murine sepsis.

Authors:  E Kerschen; I Hernandez; M Zogg; M Maas; H Weiler
Journal:  J Thromb Haemost       Date:  2015-03-31       Impact factor: 5.824

8.  Coagulation factor V mediates inhibition of tissue factor signaling by activated protein C in mice.

Authors:  Hai Po H Liang; Edward J Kerschen; Sreemanti Basu; Irene Hernandez; Mark Zogg; Shuang Jia; Martin J Hessner; Raffaella Toso; Alireza R Rezaie; José A Fernández; Rodney M Camire; Wolfram Ruf; John H Griffin; Hartmut Weiler
Journal:  Blood       Date:  2015-09-04       Impact factor: 22.113

9.  Painless Livedoid Vasculopathy in a Patient with G20210A Prothrombin Gene Mutation.

Authors:  Aibek E Mirrakhimov; Erwin Velasquez Kho; Alaa Ali
Journal:  Case Rep Med       Date:  2012-09-05

Review 10.  Activated protein C anticoagulant system dysfunction and thrombophilia in Asia.

Authors:  Naotaka Hamasaki; Hiroyuki Kuma; Hiroko Tsuda
Journal:  Ann Lab Med       Date:  2012-12-17       Impact factor: 3.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.